Khoder Noha M, Sawie Hussein G, Sharada Hayat M, Hosny Eman N, Khadrawy Yasser A, Abdulla Mohga S
Medical Physiology Department, Medical Research and Clinical Studies Institute, National Research Centre, El-Bohouth St, Giza, Egypt.
Chemistry Department, Faculty of Science, Helwan University, Cairo, Egypt.
J Diabetes Metab Disord. 2022 Jun 8;21(2):1327-1337. doi: 10.1007/s40200-022-01063-7. eCollection 2022 Dec.
The current study evaluates the effect of metformin (MET) and /or alpha lipoic acid (ALA) on hypothyroidism and its adverse effects on the cardiac, renal, and, hepatic functions in rats.
Rats were divided into five groups: control, rat model of hypothyroidism induced by propylthiouracil (PTU), rat model of hypothyroidism treated with MET, rat model of hypothyroidism treated with ALA, and rat model of hypothyroidism treated with MET and ALA. At the end of the experiment, body weight gain was determined and the blood samples were collected from orbital plexus to measure the serum levels of thyroxine (T4), triiodothyronine (T3) and thyroid stimulating hormone (TSH) by ELISA, glucose level, the activities of lactate dehydrogenase (LDH), creatine kinase MB (CK-MB), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP), and the levels of urea and creatinine spectrophotometrically.
Rat model of hypothyroidism revealed a significant decrease in T4 (p 0.001) and T3 (p 0.001) and a significant increase in TSH (p < 0.005). This was accompanied by a significant decrease in the body weight gain (p < 0.025) and a significant increase in LDH (p < 0.001), CK-MB (p < 0.001) AST (p < 0.01), ALT (p < 0.016), ALP (p < 0.001), glucose (p < 0.001), urea (p < 0.001) and creatinine (p < 0.001). MET restored T4, T3 and TSH to control values. Treatment with ALA restored T3 and TSH levels. Treatment with Met and /or ALA reduced the levels of glucose, urea and creatinine and the activities of LDH, CK-MB, AST, ALT, and ALP to control-like values. Only ALA improved the reduced body weight gain induced by hypothyroidism.
The present findings indicate the ameliorative effects of MET and /or ALA on hypothyroidism and its adverse effects on cardiac, renal and hepatic functions.
The online version contains supplementary material available at 10.1007/s40200-022-01063-7.
本研究评估二甲双胍(MET)和/或α硫辛酸(ALA)对甲状腺功能减退的影响及其对大鼠心脏、肾脏和肝脏功能的不良影响。
将大鼠分为五组:对照组、丙硫氧嘧啶(PTU)诱导的甲状腺功能减退大鼠模型组、MET治疗的甲状腺功能减退大鼠模型组、ALA治疗的甲状腺功能减退大鼠模型组、MET和ALA联合治疗的甲状腺功能减退大鼠模型组。实验结束时,测定体重增加情况,并从眶静脉丛采集血样,通过酶联免疫吸附测定法(ELISA)测量血清甲状腺素(T4)、三碘甲状腺原氨酸(T3)和促甲状腺激素(TSH)水平、血糖水平、乳酸脱氢酶(LDH)、肌酸激酶同工酶MB(CK-MB)、天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)和碱性磷酸酶(ALP)的活性,以及用分光光度法测定尿素和肌酐水平。
甲状腺功能减退大鼠模型显示T4(p < 0.001)和T3(p < 0.001)显著降低,TSH显著升高(p < 0.005)。同时伴有体重增加显著减少(p < 0.025)以及LDH(p < 0.001)、CK-MB(p < 0.001)、AST(p < 0.01)、ALT(p < 0.016)、ALP(p < 0.001)、血糖(p < 0.001)、尿素(p < 0.001)和肌酐(p < 0.001)显著升高。MET使T4、T3和TSH恢复至对照值。ALA治疗使T3和TSH水平恢复正常。MET和/或ALA治疗可使血糖、尿素和肌酐水平以及LDH、CK-MB、AST、ALT和ALP的活性降至类似对照值。只有ALA改善了甲状腺功能减退引起的体重增加减少的情况。
本研究结果表明MET和/或ALA对甲状腺功能减退及其对心脏、肾脏和肝脏功能的不良影响具有改善作用。
在线版本包含可在10.1007/s40200-022-01063-7获取的补充材料。